Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

How Autism Research ETF ASD Can Deliver for Your Portfolio

BY | ETF Database
12:43 pm ET 07/29/26 | 0 VIEWS
  • Related Symbols
  • ASD
ETFs allow investors a plethora of ways to express themselves while also pursuing performance. With each passing year, new ETFs arrive to help investors meet their personal and financial goals. The Defiance Autism Impact ETF (ASD) aims to invest in supporting individuals on the autism spectrum, while also providing some positive returns.Key Takeaways: The autism research-focused ETF ASD has returned 10.3% since it launched on June 1. The strategy’s profits will all be donated to important causes tied to supporting people with autism for the first two years of operation. Its top holding returned 209% YTD as of the end of July. ASD charges 79 basis points to track the VettaFi Autism Impact Index. That index provides an equal-weighted index approach to developed market companies in the space. Then, the ETF donates profits to organizations in autism research and care, as well as those who provide access to resources for autistic people. See more: VettaFi’s Murphy Wins Bloomberg’s ETF IQ Challenge The strategy takes that approach and provides investors with diversification across healthcare, behavioral services, assistive tech, and more. Its equal weighting helps it avoid overreliance on one firm or another. ASD will donate 100% of its net advisory profits for the first two years following launch, and no less than 50% after that. Since launch, ASD has provided some solid performance. The autism research ETF has returned 10.3% since launch according to ETF Database data. That brings it close to the average for the ETF Database health & biotech equities category, which comes in at 14% for that time. Over the last month, meanwhile, the fund has outperformed that average.ASD's Contribution to Autism Research and ReturnsTogether, that puts ASD in an intriguing position. Its ability to perform makes it a worthy option for those who want exposure to such an important cause. The fund’s top holding, Definium Therapeutics (DFTX), has returned a remarkable 209% YTD. That kind of performance can help investors diversify away from AI and do some good at the same time, with the autism research ETF an appealing fund to watch. For more news, information, and analysis, visit the Thematic Investing Content Hub. VettaFi LLC (“VettaFi”) is the index provider for ASD for which it receives an index licensing fee. However, ASD is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of ASD.

More Commentary

Inflation Isnt Gone Yet: Give Real Asset ETFs a Chance
BY | ETF Database
12:55 pm ET 07/29/26 | 0 VIEWS
As Small-Caps Rise, Pair These ETFs for Value, Growth Views
BY | ETF Database
11:32 am ET 07/29/26 | 3 VIEWS
Beyond Money Markets: Unlock Premium Yields With CLO ETFs
BY | ETF Database
6:10 am ET 07/29/26 | 14 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.